Orbital shows 2023’s venture funding scene is far from stratospheric
The group’s $270m series A, big for 2023, is not that impressive compared with other years.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
Spybiotech seeks new vaccines
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.
Flotations fail to bounce back
2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.
Ionis gets into gene editing
The company insists its $80m tie-up with Metagenomi will not lead to a loss of focus.
